Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome analysis of Co-IP samples from NCI-H1299 cell nuclear lysate with anti-AGO2 and anti-TNRC6A antibody.

ABSTRACT: Proteome analysis of Co-IP samples from NCI-H1299 cell nuclear lysate with anti-AGO2 and anti-TNRC6A antibody.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Masahiko Kuroda

PROVIDER: PXD017408 | JPOST Repository | Sat Feb 06 00:00:00 GMT 2021

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	001_exKK0690-1_Control_IgG.raw	Raw
	002_exKK0690-2_AGO2.raw	Raw
	003_exKK0690-3_TNRC6A.raw	Raw
	KK0690_Re-analysis.sdia	Other

Items per page:

1 - 4 of 4

Publications

Nuclear microRNAs release paused Pol II via the DDX21-CDK9 complex.

Ohno Shin-Ichiro SI Oikawa Keiki K Tsurui Toshiaki T Harada Yuichirou Y Ono Kana K Tateishi Mizumo M Mirza Aashiq A Takanashi Masakatsu M Kanekura Kosuke K Nagase Kumiko K Shimada Yoshihisa Y Kudo Yujin Y Ikeda Norihiko N Ochiya Takahiro T Wang Xiaozhong X Kuroda Masahiko M

Cell reports 20220401 2

RNA activation (RNAa) is an uncharacterized mechanism of transcriptional activation mediated by small RNAs, such as microRNAs (miRNAs). A critical issue in RNAa research is that it is difficult to distinguish between changes in gene expression caused indirectly by post-transcriptional regulation and direct induction of gene expression by RNAa. Therefore, in this study, we seek to identify a key factor involved in RNAa, using the induction of ZMYND10 by miR-34a as a system to evaluate RNAa. We id ...[more]

PMID: 35417682

Similar Datasets

NCI-H460 gene expression analysis after in vivo treatment with anti-PD1 antibody

Project description:Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 axis have made a breakthrough in the treatment of non-small cell lung cancer (NSCLC). However, a paradoxical boost in tumor growth was reported in a fraction of NSCLC patients after ICIs administration: a novel pattern of cancer progression defined “hyperprogressive disease” (HPD). Because the mechanism of HPD onset has not completely elucidated yet, this study aimed at investigating the cellular and molecular bases of this clinical phenomenon. Pre-treatment histological samples obtained from NSCLC patients were evaluated by immunohistochemistry (IHC) for immune cell infiltrate. Tissue samples from all patients with HPD showed tumor-infiltration by M2-like macrophages. To validate these findings in preclinical models, we utilized athymic nude mice that, lacking T-cells that may cloud the results, represent a suitable model to evaluate the role of macrophages in determining HPD. Immunodeficient mice were injected with human NSCLC NCI-H460 cell line, treated with anti-PD-1 antibody and tumor growth was evaluated over time. Anti-PD-1 treated H460 tumor-bearing mice showed HPD-like tumor growth as well as an increase in macrophage infiltration compared to control group. Interestingly, in these in vivo models, HPD-like growth, triggered by anti-PD-1 treatment, was dependent of anti-PD-1 antibody Fc domain. These results suggest that macrophages are the major players in HPD development and that FcR engagement on macrophages may determine a functional reprogramming of these immune cells toward a more aggressive and pro-tumorigenic phenotype, eventually inducing HPD.

2023-01-11 | GSE210547 | GEO

NCI-H460 gene expression analysis after in vivo treatment with anti-PD1 antibody

Project description:NCI-H460 gene expression analysis after in vivo treatment with anti-PD1 antibody

| PRJNA866142 | ENA

LC-MS/MS after anti-PUM1 and anti-PUM2 co-immunoprecipitation.

Project description:In order to identify the protein co-factors of PUMILIO1 and PUMILIO2 in TCam-2 cell line, co-IP of these proteins performed followed mass spectrometry analysis for protein identification. Six biological replicates of co-IP with anti-PUM1, anti-PUM2 antibodies and anti-IgG were performed. Three biological replicates were performed without RNase A treatment, and another three biological replicates of co-IPs with 100 mg/ml RNase A.

2020-04-23 | PXD011948 | Pride

NCI-H460-LNM35 vs NCI-H460-N15

Project description:Comparing genome-wide gene expression profiles of highly metastatic lung cancer cell line NCI-H460-LNM35 vs low metastatic parental clone NCI-H460-N15 Keywords: Expression profiling with cDNA microarray

2010-08-21 | GSE16649 | GEO

Transcriptome profiling of Anlotinib-resistant NCI-H1975 and Anlotinib-treated Anlotinib-resistant NCI-H1975

Project description:Further to our previous study (E-MTAB-5997), here we performed transcriptome profiling on Anlotinib-resistant NCI-H1975 and Anlotinib-treated Anlotinib-resistant NCI-H1975, and would like to understand the effects of Anlotinib on Anlotinib-resistant NCI-H1975 cell, compare the different transcriptome profiling on NCI-H1975 cells and Anlotinib-resistant NCI-H1975 cells, sought to find the biomarker for explaining Anlotinib resistance.

2019-07-01 | E-MTAB-7068 | biostudies-arrayexpress

NCI-60 Cancer Cell Line

Project description:NCI-60 cancer cell lines were profiled with their genome-wide gene expression patterns using Affymetrix HG-U133A chips. Keywords: NCI-60 cancer cell line expression profiling

2009-08-26 | GSE5846 | GEO

Evaluation of NCI-7 Cell Line Panel

Project description:Reference materials are vital to benchmarking the reproducibility of clinical tests and essential for monitoring laboratory performance for clinical proteomics. The reference material utilized for mass spectrometric analysis of the human proteome would ideally contain enough proteins to be suitably representative of the human proteome, as well as exhibit a stable protein composition in different batches of sample regeneration. Previously, The Clinical Proteomic Tumor Analysis Consortium (CPTAC) utilized PDX-derived comparative reference (CompRef) materials for the longitudinal assessment of proteomic performance, however, inherent drawbacks of PDX-derived material has resulted in efforts to identify a new source of CompRef material. In this study, we examined the utility of using a panel of seven cancer cell lines, NCI-7 Cell Line Panel, as a reference material for mass spectrometric analysis of the human proteome. Our results showed that not only is the NCI-7 material suitable for benchmarking laboratory sample preparation methods, but NCI-7 sample generation is highly reproducible at both the global and phosphoprotein levels. In addition, the predicted genomic and experimental coverage of the NCI-7 proteome suggests the NCI-7 material may also have applications as a universal standard proteomic reference.

2018-05-14 | PXD008952 | Pride

Expression data from NCI-H1299 and NCI-H1299/CDDP cells

Project description:Expression data from NCI-H1299 and NCI-H1299/CDDP cells

| PRJNA1062721 | ENA

Gene expression data from NCI-H295R cell line treated with rottlerin samples.

Project description:Pediatric adrenocortical tumor (ACT) is a rare neoplasm with high heterogeneity, exhibiting an incidence 10 to 15 times higher in the south and southeast regions of Brazil when compared to the global incidence.In this context, our aim was to analyze the gene expression profile in the adrenocortical carcinoma cell line (NCI-H295R) after treatment with the compound rottlerin.

2024-02-18 | GSE255729 | GEO

NCI Exceptional Responders Initiative

Project description:NCI Exceptional Responders Initiative

| PRJNA325186 | ENA